Hospitalization Cost and Its Structural Variation for Four Kinds of Malignant Tumors in China from 2013 to 2017
1.School of Public Health and Management,Weifang Medical University,Weifang 261053,China
2.“Health Shandong” Severe Social Risk Prevention and Management Collaborative Innovation Center,Weifang 261053,China
3.The Innovation Center for Social Risk Governance in Health,Shanghai 200032,China
*Corresponding author:HUANG Dongmei,Professor;E-mail:hdongm@126.com
SONG Yannan,YIN Wenqiang,LIU Min, et al. Hospitalization Cost and Its Structural Variation for Four Kinds of Malignant Tumors in China from 2013 to 2017 [J]. Chinese General Practice, 2020, 23(6): 649-655. DOI: 10.12114/j.issn.1007-9572.2019.00.823.
宋燕楠,尹文强,刘敏等. 2013—2017年我国四种恶性肿瘤住院费用水平及结构变动度分析[J]. 中国全科医学, 2020, 23(6): 649-655. DOI: 10.12114/j.issn.1007-9572.2019.00.823.
[1]周英武,任明,胡镜清.中医慢性病防治科研成果转化现状分析[J].中医药管理杂志,2018,26(2):5-8.
[2]郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.DOI:10.3760/cma.j.issn.0253-3766.2019.01.008.
ZHENG R S,SUN K X,ZHANG S W,et al.Report of cancer epidemiology in China,2015[J].Chinese Journal of Oncology,2019,41(1):19-28.DOI:10.3760/cma.j.issn.0253-3766.2019.01.008.
[3]国家发展改革委,国家卫生计生委,人力资源社会保障部,等.关于印发推进医疗服务价格改革意见的通知[EB/OL].(2016-07-01)[2019-09-25].http://www.ndrc.gov.cn/fzgggz/jggl/zcfg/201607/t20160706_810599.html.
[4]国家卫生和计划生育委员会.2014中国卫生和计划生育统计年鉴[M].北京:中国协和医科大学出版社,2014.
[5]国家卫生和计划生育委员会.2015中国卫生和计划生育统计年鉴[M].北京:中国协和医科大学出版社,2015.
[6]国家卫生和计划生育委员会.2016中国卫生和计划生育统计年鉴[M].北京:中国协和医科大学出版社,2016.
[7]国家卫生和计划生育委员会.2017中国卫生和计划生育统计年鉴[M].北京:中国协和医科大学出版社,2017.
[8]国家卫生健康委员会.2018中国卫生健康统计年鉴[M].北京:中国协和医科大学出版社,2018.
[9]耿素梅.结构变动度在医疗费用结构分析中的应用[J].管理观察,2015(18):156-157,160.DOI:10.3969/j.issn.1674-2877.2015.18.060.
[10]国家发展改革委.国家发展改革委关于全面深化价格机制改革的意见[EB/OL].(2017-11-08)[2019-09-25].http://www.ndrc.gov.cn/zcfb/zcfbtz/201711/t20171110_866776.html.
[11]两省宣布:全面取消耗材加成(附31省进展)[EB/OL].(2019-07-08)[2019-08-25].http://www.sohu.com/a/325465822_490432.
[12]邱五七,董佩,毛阿燕,等.北京市食管癌患者次均住院费用的新灰色关联分析[J].中国病案,2016,17(10):66-70.
QIU W Q,DONG P,MAO A Y,et al.New grey correlation analysis on the average hospitalization expenses per time of patients with esophagus cancer[J].Chinese Medical Record,2016,17(10):66-70.
[13]丁玲玲,王力男,李芬,等.基于结构变动度的上海市医疗收入分析[J].中国卫生经济,2017,36(8):73-76.DOI:10.7664/CHE20170817.
DING L L,WANG L N,LI F,et al.Analysis on medical income of Shanghai based on degree of structure variation[J].Chinese Health Economics,2017,36(8):73-76.DOI:10.7664/CHE20170817.
[14]祝豫,张歆,黄卫东,等.肺癌非手术患者住院费用的灰色关联分析[J].中国卫生经济,2017,36(12):82-84.DOI:10.7664/CHE20171222.
ZHU Y,ZHANG X,HUANG W D,et al.Gray relational analysis on the hospitalization expenses of non-surgical patients with lung cancer[J].Chinese Health Economics,2017,36(12):82-84.DOI:10.7664/CHE20171222.
[15]雷海科,周琦,邱惠,等.胃癌患者住院费用灰色关联分析[J].中国肿瘤,2016,25(9):672-676.DOI:10.11735/j.issn.1004-0242.2016.09.A002.
LEI H K,ZHOU Q,QIU H,et al.Grey correlation analysis of hospital costs in patients with gastric carcinoma[J].China Cancer,2016,25(9):672-676.DOI:10.11735/j.issn.1004-0242.2016.09.A002.
[16]李小升,石菊芳,雷海科,等.大肠癌患者住院费用灰色关联分析[J].中国病案,2016,17(1):66-69.
LI X S,SHI J F,LEI H K,et al.Grey correlation analysis on the hospitalization costs of patients with colorectal neoplasm[J].Chinese Medical Record,2016,17(1):66-69.
[17]余明,干荣富.抗肿瘤药物市场现状、价格和规制政策浅析[J].世界临床药物,2016,37(12):854-859.DOI:10.13683/j.wph.2016.12.014.
YU M,GAN R F.Drug market status and regulation policy analysis of anti-tumor drugs[J].World Clinical Drugs,2016,37(12):854-859.DOI:10.13683/j.wph.2016.12.014.
[18]梁兰,胡建萍,何东梅.1408例鼻咽癌患者内科治疗住院费用的新灰色关联分析[J].中国病案,2018,19(11):41-45.DOI:10.3969/j.issn.1672-2566.2018.11.016.
LIANG L,HU J P,HE D M.New grey correlation analysis on the average hospitalization expenses per time of 1408 cases of medical treatment of nasopharyngeal carcinoma(NPC)[J].Chinese Medical Record,2018,19(11):41-45.DOI:10.3969/j.issn.1672-2566.2018.11.016.
[19]张晟.世界抗癌药物价格对比,中国占第几?[EB/OL].(2016-06-12)[2019-08-25].https://www.sohu.com/a/82689623_377332.
[20]齐璐璐,沈辉.利益相关者理论视野下公立医院的文化价值取向[J].中国卫生资源,2014(5):357-359.DOI:10.3969/j.issn.1007-953X.2014.05.015.
QI L L,SHEN H.Cultural value orientation of public hospitals in the view of stakeholder theory[J].Chinese Health Resources,2014(5):357-359.DOI:10.3969/j.issn.1007-953X.2014.05.015.
[21]姚芳,石春雷,刘成成,等.中国1996—2015年胃癌经济负担研究的系统评价[J].中华预防医学杂志,2017,51(8):756-762.DOI:10.3760/cma.j.issn.0253-9624.2017.08.018.
YAO F,SHI C L,LIU C C,et al.Economic burden of stomach cancer in China during 1996—2015:a systematic review[J].Chin J Prev Med,2017,51(8):756-762.DOI:10.3760/cma.j.issn.0253-9624.2017.08.018.
[22]徐萍,谢琪.纤支镜检查在X线胸片阴性肺癌诊断中的应用价值[J].山东医药,2009,49(21):66.DOI:10.3969/j.issn.1002-266X.2009.21.042.
[23]孙群,谭玲,杨练,等.四川省县级医院药品零差率后员工工作效率变化研究[J].中国卫生产业,2015(3):60-61.